Inside informationEnglish
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Nanobiotix
- Filed
- 17/09/2025, 22:15
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 110757_20250917